Cargando…

Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients

Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to limited biopsy information, impracticality of repeated biopsies, and cancer biomarker fallibility. Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ying-Chi, Wang, Dong, Jin, Lan, Yao, Hong-Wei, Zhang, Jing-Hui, Wang, Jin, Zhao, Xiao-Mu, Shen, Chun-Ying, Chen, Wei, Wang, Xue-Liang, Shi, Rong, Chen, Si-Yi, Zhang, Zhong-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066652/
https://www.ncbi.nlm.nih.gov/pubmed/29914973
http://dx.doi.org/10.1042/BSR20180322
_version_ 1783343003503427584
author Yang, Ying-Chi
Wang, Dong
Jin, Lan
Yao, Hong-Wei
Zhang, Jing-Hui
Wang, Jin
Zhao, Xiao-Mu
Shen, Chun-Ying
Chen, Wei
Wang, Xue-Liang
Shi, Rong
Chen, Si-Yi
Zhang, Zhong-Tao
author_facet Yang, Ying-Chi
Wang, Dong
Jin, Lan
Yao, Hong-Wei
Zhang, Jing-Hui
Wang, Jin
Zhao, Xiao-Mu
Shen, Chun-Ying
Chen, Wei
Wang, Xue-Liang
Shi, Rong
Chen, Si-Yi
Zhang, Zhong-Tao
author_sort Yang, Ying-Chi
collection PubMed
description Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to limited biopsy information, impracticality of repeated biopsies, and cancer biomarker fallibility. Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene mutations in tumors, in addition to monitoring disease progression and response to treatment. We analyzed ctDNA mutations and concentrations in 47 early- and late-stage CRC patients using a targetted sequencing approach using a panel that covers 50 cancer-related genes. ctDNA mutations in 37 genes were identified in 93.6% of the patients (n=47). The results showed that TP53, PIK3CA, APC, and EGFR were the most frequently mutated genes. Stage IV patients had significantly higher ctDNA concentration than Stage I patients, and increased ctDNA concentration correlated with increased tumor size. Additionally, ctDNA detection was found to be a greater predictor of disease when compared with five known commonly used tumor biomarkers. The present study supports the use of ctDNA as a liquid biopsy to gain clinical tumor information that may facilitate early diagnosis and treatment and improve CRC patient prognosis.
format Online
Article
Text
id pubmed-6066652
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-60666522018-08-10 Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients Yang, Ying-Chi Wang, Dong Jin, Lan Yao, Hong-Wei Zhang, Jing-Hui Wang, Jin Zhao, Xiao-Mu Shen, Chun-Ying Chen, Wei Wang, Xue-Liang Shi, Rong Chen, Si-Yi Zhang, Zhong-Tao Biosci Rep Research Articles Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to limited biopsy information, impracticality of repeated biopsies, and cancer biomarker fallibility. Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene mutations in tumors, in addition to monitoring disease progression and response to treatment. We analyzed ctDNA mutations and concentrations in 47 early- and late-stage CRC patients using a targetted sequencing approach using a panel that covers 50 cancer-related genes. ctDNA mutations in 37 genes were identified in 93.6% of the patients (n=47). The results showed that TP53, PIK3CA, APC, and EGFR were the most frequently mutated genes. Stage IV patients had significantly higher ctDNA concentration than Stage I patients, and increased ctDNA concentration correlated with increased tumor size. Additionally, ctDNA detection was found to be a greater predictor of disease when compared with five known commonly used tumor biomarkers. The present study supports the use of ctDNA as a liquid biopsy to gain clinical tumor information that may facilitate early diagnosis and treatment and improve CRC patient prognosis. Portland Press Ltd. 2018-07-31 /pmc/articles/PMC6066652/ /pubmed/29914973 http://dx.doi.org/10.1042/BSR20180322 Text en © 2018 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Articles
Yang, Ying-Chi
Wang, Dong
Jin, Lan
Yao, Hong-Wei
Zhang, Jing-Hui
Wang, Jin
Zhao, Xiao-Mu
Shen, Chun-Ying
Chen, Wei
Wang, Xue-Liang
Shi, Rong
Chen, Si-Yi
Zhang, Zhong-Tao
Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
title Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
title_full Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
title_fullStr Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
title_full_unstemmed Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
title_short Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
title_sort circulating tumor dna detectable in early- and late-stage colorectal cancer patients
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066652/
https://www.ncbi.nlm.nih.gov/pubmed/29914973
http://dx.doi.org/10.1042/BSR20180322
work_keys_str_mv AT yangyingchi circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT wangdong circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT jinlan circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT yaohongwei circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT zhangjinghui circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT wangjin circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT zhaoxiaomu circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT shenchunying circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT chenwei circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT wangxueliang circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT shirong circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT chensiyi circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients
AT zhangzhongtao circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients